SCHEMBL10319986

SCHEMBL10319986

CN(C)C(=O)c1ccc(Cl)c(C(N)=O)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
HPGD P15428 5/20 0.44
HTT P42858 2/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
SLC6A2 P23975 4/20 0.40
SLC6A4 P31645 4/20 0.40
SLC6A3 Q01959 4/20 0.40
LRRK2 Q5S007 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
MAPK9 P45984 1/20 0.39
MAPK10 P53779 1/20 0.39
PDK2 Q15119 1/20 0.38
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3784574 0.87 ALDH1A1 (0.66) ALDH1A1HPGDHTTMAPTKDM4E
SCHEMBL3782207 0.81 ALDH1A1 (0.51) ALDH1A1HPGDHTTLMNAMAPT
SCHEMBL20476685 0.81 IKBKB (0.46) ALDH1A1HPGDHTTMAPTSMN1; SMN2
SCHEMBL13544758 0.80 MAPT (0.47) ALDH1A1HPGDHTTLMNAMAPT
SCHEMBL10318165 0.79 KDM4E (0.50) ALDH1A1HPGDLMNAMAPTKDM4E
SCHEMBL10322887 0.78 KMT2A (0.61) ALDH1A1HPGDHTTKMT2AHSP90AA1
SCHEMBL3787476 0.77 ALDH1A1 (0.51) ALDH1A1HPGDHTTMAPTSMN1; SMN2
SCHEMBL10323952 0.76 PLAU (0.50) ALDH1A1HPGDHTTLMNAMAPT
SCHEMBL3828279 0.76 DGAT1 (0.51) ALDH1A1HPGDSMN1; SMN2LRRK2KMT2A
SCHEMBL11299002 0.75 ALDH1A1 (0.62) ALDH1A1HPGDHTTMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012098065-A1 PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 WO claimed
WO-2012098070-A1 QUINOLINE DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 WO claimed
US-20120184548-A1 CARBOXYLIC ACID ARYL AMIDES DOMINIQUE ROMYR (US) 2012-07-19 US claimed
US-20120184542-A1 PYRIDO PYRIMIDINES ANDERSON KEVIN (US) 2012-07-19 US claimed
WO-2012098065-A1 PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 WO disclosed
WO-2012098070-A1 QUINOLINE DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 WO disclosed
US-20120184542-A1 PYRIDO PYRIMIDINES ANDERSON KEVIN (US) 2012-07-19 US disclosed
US-20120184548-A1 CARBOXYLIC ACID ARYL AMIDES DOMINIQUE ROMYR (US) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184548-A1 CARBOXYLIC ACID ARYL AMIDES GOT1, PPARG, PPARA ALDH1A1 62/4885HPGD 743/4885HTT 708/4885
US-20120184542-A1 PYRIDO PYRIMIDINES TYMS, TYMP, DPYD ALDH1A1 2619/4885HPGD 750/4885HTT 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.